| vTv Therapeutics is a holding company. Through its subsidiary, vTv Therapeutics LLC, Co. is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for diabetes. Co. has a pipeline of small molecule clinical and pre-clinical drug candidates. Co.'s primary program is TTP399, an orally administered, small molecule, liver-selective glucokinase activator for the treatment of type 1 diabetes. In addition to the studies of TTP399, Co. is conducting a Phase 1 mechanistic study of TTP399 in patients with type 1 diabetes to determine the impact of TTP399 on ketone body formation during a period of acute insulin withdrawal. The VTVT YTD return is shown above.
The YTD Return on the VTVT YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether VTVT YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the VTVT YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.